Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 1
2014 1
2020 1
2021 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

4 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: ACH-0141625
Page 1
Protease Inhibitors (HCV).
[No authors listed] [No authors listed] 2022 Jan 25. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2022 Jan 25. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31644194 Free Books & Documents. Review.
At least four HCV protease inhibitors have been approved for use in the United States (boceprevir, glecaprevir, grazoprevir, paritaprevir, simeprevir, telaprevir), and others were evaluated in clinical studies (asunaprevir, danoprevir, faldaprevir, sovaprevir, vedroprevir) …
At least four HCV protease inhibitors have been approved for use in the United States (boceprevir, glecaprevir, grazoprevir, paritaprevir, s …
Current race in the development of DAAs (direct-acting antivirals) against HCV.
De Clercq E. De Clercq E. Biochem Pharmacol. 2014 Jun 15;89(4):441-52. doi: 10.1016/j.bcp.2014.04.005. Epub 2014 Apr 13. Biochem Pharmacol. 2014. PMID: 24735613
The direct-acting antivirals (DAAs) currently in development for treatment of hepatitis C fall into four categories: (i) NS3/4A protease inhibitors: ABT-450/r, faldaprevir, asunaprevir, GS-9256, vedroprevir (GS-9451), danoprevir, MK-5172, vaniprevir, sovaprevir, ACH-2684, …
The direct-acting antivirals (DAAs) currently in development for treatment of hepatitis C fall into four categories: (i) NS3/4A protease inh …
In silico identification of strong binders of the SARS-CoV-2 receptor-binding domain.
Behloul N, Baha S, Guo Y, Yang Z, Shi R, Meng J. Behloul N, et al. Eur J Pharmacol. 2021 Jan 5;890:173701. doi: 10.1016/j.ejphar.2020.173701. Epub 2020 Oct 29. Eur J Pharmacol. 2021. PMID: 33130279 Free PMC article.
According to our screening and selection criteria, three approved antivirals (elbasvir, grazoprevir, and sovaprevir) and 4 other drugs (hesperidin, pamaqueside, diosmin, and sitogluside) were identified as potent binders of the RBD. ...
According to our screening and selection criteria, three approved antivirals (elbasvir, grazoprevir, and sovaprevir) and 4 other drug …
Meeting report: 26th International Conference on Antiviral Research.
Vere Hodge RA. Vere Hodge RA. Antiviral Res. 2013 Oct;100(1):276-85. doi: 10.1016/j.antiviral.2013.08.006. Epub 2013 Aug 21. Antiviral Res. 2013. PMID: 23973733 Free PMC article.
Topics in the clinical symposium included the current status of the anti-HCV compounds sovaprevir, ACH-3102, miravirsen and ALS-2200; the evaluation of single-tablet regimens for HIV infection; and the investigation of cytomegalovirus resistance to CMX001. ...
Topics in the clinical symposium included the current status of the anti-HCV compounds sovaprevir, ACH-3102, miravirsen and ALS-2200; …